CryoLife Revenue and Competitors

Claim your profile

Atlanta, GA USA

Location

$101.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • CryoLife's estimated annual revenue is currently $287.3M per year.(i)
  • CryoLife's estimated revenue per employee is $196,270
  • CryoLife's total funding is $101.3M.
  • CryoLife's current valuation is $753.2M. (January 2022)

Employee Data

  • CryoLife has 1464 Employees.(i)
  • CryoLife grew their employee count by -20% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2M13-13%N/AN/A
#2
$14.7M9514%$0.07BN/A
#3
$3.3M516%N/AN/A
#4
$9.6M62-11%N/AN/A
#5
$287.3M1464-20%$101.3MN/A
#6
$19.1M12348%$20.3MN/A
#7
$37.8M19520%$14.2MN/A
#8
$3.8M6011%N/AN/A
#9
$16.1M12720%N/AN/A
#10
$0.3M4-20%$2.8MN/A

CryoLife, Inc., The leader in transplant preservation, surgical adhesives and tissue engineered implantable devices makes an overwhelming commitment to the wellness and spirit of people of the world by providing state of the art implantable devices for patientsFounded in 1984, CryoLife was the first biomedical company to specialize in the low temperature preservation of human heart valves used for complex cardiac reconstruction primarily in children born with heart defects. Since those initial efforts, CryoLife’s preservation technology has expanded to include cardiac patches, saphenous veins, femoral arteries and veins as well as aorto-illiac vessels for use in central and peripheral vascular reconstruction. CryoLife’s proprietary processes for preserving these cardiovascular tissues have dramatically improved and enhanced the lives of one hundred thousand patients primarily in North America. Founded in 1984, CryoLife was the first biomedical company to specialize in the low temperature preservation of human heart valves used for complex cardiac reconstruction primarily in children born with heart defects. Since those initial efforts, CryoLife’s preservation technology has expanded to include cardiac patches, saphenous veins, femoral arteries and veins as well as aorto-illiac vessels for use in central and peripheral vascular reconstruction. CryoLife’s proprietary processes for preserving these cardiovascular tissues have dramatically improved and enhanced the lives of one hundred thousand patients primarily in North America. With studies beginning in 1991, Steven Goldstein, Ph.D., CryoLife’s Senior Director of Tissue Technologies, pushed the company into the forefront of a new approach in implantable tissue-based devices with the development of a decellularization technology that became known as the SynerGraft® process The SynerGraft process is designed to remove cells and antigens from the implantable tissues while preserving the integrity of the tissues’ collagen matrix. SynerGraft processed human pulmonary heart valves were cleared by the FDA in May of 2008 and SynerGraft processed pulmonary cardiac patch tissue was cleared by the FDA in August 2009. SynerGraft processed cardiac patches and valves are used by surgeons for complex cardiac reconstruction and valve replacement procedures.

keywords:N/A

$101.3M

Total Funding

1464

Number of Employees

$287.3M

Revenue (est)

-20%

Employee Growth %

$753.2M

Valuation

N/A

Accelerator

CryoLife News

2022-04-20 - Valvular Heart Disease Treatment Market Size, Scope And ...

... B. Braun Melsungen AG, Abbott Laboratories, Medtronic Plc, CryoLife Inc., LivaNova Plc, Micro Interventional Devices Inc.

2022-04-20 - Heart Valve Repair and Replacement Devices Market Size ...

Heart Valve Repair and Replacement Devices Market Size 2022-2029| Key Players – Abbott, Boston Scientific, CryoLife, Edwards Lifesciences.

2022-04-19 - Heart Valve Devices Market Size, Scope And Forecast | Abbott ...

Abbott, CryoLife, Boston Scientific, Edward Lifesciences, TTK HealthCare, JenaValve Technology, Medtronic, Neovasc, Sorin Group,...

2021-10-20 - CryoLife : Announces Release Date and Teleconference Call Details for Third Quarter 2021 Financial Results

ATLANTA, Oct. 20, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2021 financial results will be released on Thursday, November 4, 2021 after the market closes. On that day, the Company ...

2021-07-29 - CryoLife Announces Sale of PerClot to Baxter

ATLANTA, July 29, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has completed the sale of its PerClot product line to a subsidiary of Baxter International, Inc. ("Baxter") (NYSE: BAX ), for up ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$540.2M17549%N/A
#2
$368.2M18141%N/A
#3
$842.2M18346%N/A
#4
$1574.1M387737%N/A
#5
$2599.7M56275%N/A